Day One Biopharmaceuticals’ (DAWN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a $40.00 target price on the stock.

Several other equities research analysts have also commented on DAWN. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. JPMorgan Chase & Co. reduced their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC lifted their target price on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock opened at $14.65 on Thursday. Day One Biopharmaceuticals has a fifty-two week low of $10.90 and a fifty-two week high of $18.07. The company has a market cap of $1.29 billion, a PE ratio of -14.22 and a beta of -1.51. The business’s 50-day simple moving average is $14.19 and its two-hundred day simple moving average is $14.39.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the prior year, the business posted ($0.54) earnings per share. As a group, analysts predict that Day One Biopharmaceuticals will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the sale, the insider now directly owns 1,127,535 shares in the company, valued at $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the sale, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Charles N. York II sold 2,633 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $36,862.00. Following the completion of the transaction, the chief financial officer now owns 232,485 shares of the company’s stock, valued at approximately $3,254,790. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,748 shares of company stock worth $689,072 in the last 90 days. 8.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after buying an additional 1,002 shares in the last quarter. ProShare Advisors LLC grew its holdings in Day One Biopharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after buying an additional 1,447 shares during the last quarter. SteelPeak Wealth LLC raised its stake in Day One Biopharmaceuticals by 9.8% during the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after purchasing an additional 1,550 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Day One Biopharmaceuticals by 16.9% in the third quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock valued at $376,000 after buying an additional 3,900 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in shares of Day One Biopharmaceuticals by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company’s stock worth $887,000 after purchasing an additional 5,070 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.